Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ-depleted HSCT for Refractory Crohn's Disease
NCT06986382Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Jul 2025
- Primary completion
- Jul 2037
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells in Crohn's disease (CD), sponsored by Stanford University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells
03
Conditions
Crohn's disease (CD)
Beyond the preview
Go deeper on NCT06986382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986382.